IRIS Accounts Production v26.1.0.640 10524404 Board of Directors 1.1.25 31.12.25 31.12.25 0 0 false true false false true false Fair value model Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 10524404 2024-12-31 10524404 2025-12-31 10524404 2025-01-01 2025-12-31 10524404 2023-12-31 10524404 2024-01-01 2024-12-31 10524404 2024-12-31 10524404 ns15:EnglandWales 2025-01-01 2025-12-31 10524404 ns14:PoundSterling 2025-01-01 2025-12-31 10524404 ns10:Director1 2025-01-01 2025-12-31 10524404 ns10:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 10524404 ns10:SmallEntities 2025-01-01 2025-12-31 10524404 ns10:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 10524404 ns10:SmallCompaniesRegimeForDirectorsReport 2025-01-01 2025-12-31 10524404 ns10:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 10524404 ns10:FullAccounts 2025-01-01 2025-12-31 10524404 ns10:OrdinaryShareClass1 2025-01-01 2025-12-31 10524404 ns10:Director2 2025-01-01 2025-12-31 10524404 ns10:RegisteredOffice 2025-01-01 2025-12-31 10524404 ns5:CurrentFinancialInstruments 2025-12-31 10524404 ns5:CurrentFinancialInstruments 2024-12-31 10524404 ns5:Non-currentFinancialInstruments 2025-12-31 10524404 ns5:Non-currentFinancialInstruments 2024-12-31 10524404 ns5:ShareCapital 2025-12-31 10524404 ns5:ShareCapital 2024-12-31 10524404 ns5:RetainedEarningsAccumulatedLosses 2025-12-31 10524404 ns5:RetainedEarningsAccumulatedLosses 2024-12-31 10524404 ns5:Secured 2025-12-31 10524404 ns5:Secured 2024-12-31 10524404 ns10:OrdinaryShareClass1 2025-12-31 10524404 ns5:RetainedEarningsAccumulatedLosses 2024-12-31 10524404 ns5:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31

REGISTERED NUMBER: 10524404 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

RADPHARM PROPERTY INVESTMENTS LIMITED

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 4 |

RADPHARM PROPERTY INVESTMENTS LIMITED

COMPANY INFORMATION

FOR THE YEAR ENDED 31 DECEMBER 2025

| DIRECTORS: | S Iqbal

| Mrs A Iqbal

| REGISTERED OFFICE: | 2 Cedargrove

| Hagley

| Stourbridge

| West Midlands

| DY9 0DR

| REGISTERED NUMBER: | 10524404 (England and Wales)

| ACCOUNTANTS: | Ashcrofts Accountants Limited

| 2 Cedargrove

| Hagley

| Stourbridge

| West Midlands

| DY9 0DR

| BANKERS: | Barclays Bank plc

| 51 Mosley Street

| Manchester

| M60 2AU

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

BALANCE SHEET

31 DECEMBER 2025

| 2025 |  | 2024

| Notes | £ | £ |

FIXED ASSETS

Investment property | 4 | 421,950 |  | 421,950 |  |

CURRENT ASSETS

Debtors | 5 | 10,000 |  | 10,000 |  |

Cash at bank | 8,864 |  | 76,149 |  |

18,864 |  | 86,149 |  |

CREDITORS

Amounts falling due within one year | 6 | (91,228 | ) | (161,572 | ) |

NET CURRENT LIABILITIES | (72,364 | ) | (75,423 | ) |

TOTAL ASSETS LESS CURRENT LIABILITIES | 349,586 |  | 346,527 |  |

CREDITORS

Amounts falling due after more than one year | 7 | (225,122 | ) | (225,122 | ) |

NET ASSETS | 124,464 |  | 121,405 |  |

CAPITAL AND RESERVES

Called up share capital | 10 | 100 |  | 100 |  |

Retained earnings | 11 | 124,364 |  | 121,305 |  |

SHAREHOLDERS' FUNDS | 124,464 |  | 121,405 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

BALANCE SHEET - continued

31 DECEMBER 2025

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 5 April 2026 and were signed on its behalf by:

S Iqbal - Director

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

1. | STATUTORY INFORMATION

| Radpharm Property Investments Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Investment property

| Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was NIL (2024 - NIL).

4. | INVESTMENT PROPERTY

| Total

£ |

| FAIR VALUE

| At 1 January 2025

| and 31 December 2025 | 421,950 |  |

| NET BOOK VALUE

| At 31 December 2025 | 421,950 |  |

| At 31 December 2024 | 421,950 |  |

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Other debtors | 10,000 |  | 10,000 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade creditors | - |  | 918 |  |

| Corporation tax | 718 |  | 17,144 |  |

| Other creditors | 87,167 |  | 140,167 |  |

| Directors' loan accounts | 2,589 |  | 2,589 |  |

| Accruals and deferred income | 754 |  | 754 |  |

91,228 |  | 161,572 |  |

7. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

2025 | 2024 |

£ | £ |

| Bank loans (see note 8) | 225,122 |  | 225,122 |  |

| Amounts falling due in more than five years:

| Repayable by instalments

| Bank loans more 5 yr by instal | 225,122 |  | 225,122 |  |

8. | LOANS

| An analysis of the maturity of loans is given below:

2025 | 2024 |

£ | £ |

| Amounts falling due in more than five years:

| Repayable by instalments

| Bank loans more 5 yr by instal | 225,122 |  | 225,122 |  |

9. | SECURED DEBTS

| The following secured debts are included within creditors:

2025 | 2024 |

£ | £ |

| Bank loans | 225,122 |  | 225,122 |  |

10. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 100 | Ordinary | £1 | 100 |  | 100 |  |

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

11. | RESERVES

| Retained

| earnings

£ |

| At 1 January 2025 | 121,305 |  |

| Profit for the year | 3,059 |  |

| At 31 December 2025 | 124,364 |  |

12. | DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

| At 31 December 2025 there was a loan from Mr S Iqbal of £2,589 (2024: £2,589). This unsecured loan is interest free and repayable on demand.

13. | RELATED PARTY DISCLOSURES

| At 31 December 2025, there was a loan from Radcliffe Pharmacy Limited of £87,167 (2024: £140,167), a company in which Mr S Iqbal is a director. This unsecured loan is interest free and repayable on demand.